ERBB2 and neoplasm: Current therapeutic modalities, encompassing surgical resection, cytotoxic chemotherapy, and Human epidermal growth factor receptor 2 (HER2)-targeted agents, demonstrate limited effectiveness against tumor heterogeneity, metastatic dissemination, and therapy resistance mechanisms potentiated by the immunosuppressive tumor microenvironment (TME) (13–16).